{
    "clinical_study": {
        "@rank": "166682", 
        "arm_group": [
            {
                "arm_group_label": "buprenorphine", 
                "arm_group_type": "Active Comparator", 
                "description": "depot buprenorphine"
            }, 
            {
                "arm_group_label": "buprenorphine and ultra-low dose naloxone", 
                "arm_group_type": "Experimental", 
                "description": "depot buprenorphine and naloxone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to develop a clinical protocol to detoxify patients from\n      opiates to naltrexone using buprenorphine and to develop pilot data for a grant application\n      for a controlled study of the efficacy of the new clinical protocol for outpatients."
        }, 
        "brief_title": "Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2", 
        "completion_date": {
            "#text": "November 2009", 
            "@type": "Actual"
        }, 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Males/Females, ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported\n        use within the last 30 days. Agreeable to conditions of study and signed informed consent.\n\n        Exclusion Criteria:\n\n        psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nursing women. Dependent on etoh or benzodiazepines or other sedative-hypnotics.\n        Acute hepatitis. Other medical conditions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000299", 
            "org_study_id": "NIDA-09260-2", 
            "secondary_id": [
                "P50DA009260", 
                "P50-09260-2"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "buprenorphine", 
                "buprenorphine and ultra-low dose naloxone"
            ], 
            "intervention_name": "Buprenorphine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Naltrexone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rapid Opiate Detoxification & Naltrexone Induction Using Bup.", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "opiate craving is measured on each test day.", 
                "measure": "Opiate craving", 
                "safety_issue": "No", 
                "time_frame": "10 test days"
            }, 
            {
                "description": "opiate withdrawal symptoms are documented for each test day", 
                "measure": "Opiate withdrawal symptoms", 
                "safety_issue": "No", 
                "time_frame": "10 test days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000299"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Los Angeles", 
            "investigator_full_name": "Walter Ling", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of California, Los Angeles", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}